{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:22Z","timestamp":1792787302082,"version":"4.5.0"},"reference-count":20,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Boehringer Ingelheim International GmbH"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2023,2,2]]},"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the rate of decline in forced vital capacity (FVC), and the effect of nintedanib on the rate of decline in FVC, in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD) who had risk factors for rapid decline in FVC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The SENSCIS trial enrolled subjects with SSc and fibrotic ILD of \u226510% extent on high-resolution CT. The rate of decline in FVC over 52 weeks was analysed in all subjects and in those with early SSc (&lt;18 months since first non-Raynaud symptom), elevated inflammatory markers (C reactive protein \u22656\u2009mg\/L and\/or platelets \u2265330\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L) or significant skin fibrosis (modified Rodnan skin score (mRSS) 15\u201340 or mRSS \u226518) at baseline.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the placebo group, the rate of decline in FVC was numerically greater in subjects with &lt;18 months since first non-Raynaud symptom (\u2212167.8\u2009mL\/year), elevated inflammatory markers (\u2212100.7\u2009mL\/year), mRSS 15\u201340 (\u2212121.7\u2009mL\/year) or mRSS \u226518 (\u2212131.7 mL\/year) than in all subjects (\u221293.3\u2009mL\/year). Nintedanib reduced the rate of FVC decline across subgroups, with a numerically greater effect in patients with these risk factors for rapid FVC decline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In the SENSCIS trial, subjects with SSc-ILD who had early SSc, elevated inflammatory markers or extensive skin fibrosis had a more rapid decline in FVC over 52 weeks than the overall trial population. Nintedanib had a numerically greater effect in patients with these risk factors for rapid ILD progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002859","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T10:20:37Z","timestamp":1676542837000},"page":"e002859","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":31,"title":["Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct02597933","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1412-4453","authenticated-orcid":false,"given":"Dinesh","family":"Khanna","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Scleroderma Program, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7192-9149","authenticated-orcid":false,"given":"Toby M","family":"Maher","sequence":"additional","affiliation":[{"name":"Keck School of Medicine, University of Southern California, Los Angeles, California, USA"},{"name":"National Heart and Lung Institute, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3750-6569","authenticated-orcid":false,"given":"Elizabeth R","family":"Volkmann","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University of California, David Geffen School of Medicine, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6149-0002","authenticated-orcid":false,"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[{"name":"Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6271-7945","authenticated-orcid":false,"given":"Vanessa","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ghent University Hospital, Ghent, Belgium"},{"name":"Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium"},{"name":"Department of Internal Medicine, Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8059-9978","authenticated-orcid":false,"given":"Shervin","family":"Assassi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University of Texas McGovern Medical School, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4402-2159","authenticated-orcid":false,"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[{"name":"Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Care Medicine, Thoraxklinik, University of Heidelberg and German Center for Lung Research, Heidelberg, Germany"},{"name":"Department of Pneumology, RKH Clinic Ludwigsburg, Ludwigsburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6467-7422","authenticated-orcid":false,"given":"Anna-Maria","family":"Hoffmann-Vold","sequence":"additional","affiliation":[{"name":"Inflammatory and Fibrotic Rheumatic Disease Research Area, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-6136","authenticated-orcid":false,"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3493-3234","authenticated-orcid":false,"given":"Christian","family":"Stock","sequence":"additional","affiliation":[{"name":"Global Biostatistics and Data Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Alves","sequence":"additional","affiliation":[{"name":"TA Inflammation Med, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Sambevski","sequence":"additional","affiliation":[{"name":"TA Inflammation Med, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3975-8938","authenticated-orcid":false,"given":"Christopher P","family":"Denton","sequence":"additional","affiliation":[{"name":"University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"key":"2025090312263340000_9.1.e002859.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211448"},{"key":"2025090312263340000_9.1.e002859.2","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1164\/rccm.201903-0486OC","article-title":"Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort","volume":"200","author":"Hoffmann-Vold","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2025090312263340000_9.1.e002859.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213708"},{"key":"2025090312263340000_9.1.e002859.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217455"},{"key":"2025090312263340000_9.1.e002859.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370903"},{"key":"2025090312263340000_9.1.e002859.6","unstructured":"Volkmann E , Li N , Roth M , et al . Sex differences in severity and progression of interstitial lung disease in systemic sclerosis: what we have learned from clinical trials. Arthritis Rheumatol 2020;72."},{"key":"2025090312263340000_9.1.e002859.7","first-page":"S126","article-title":"The role of inflammatory markers in assessment of disease activity in systemic sclerosis","volume":"36","author":"Ross","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312263340000_9.1.e002859.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213455"},{"key":"2025090312263340000_9.1.e002859.9","doi-asserted-by":"crossref","DOI":"10.1186\/ar3125","article-title":"Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort","volume":"12","author":"Assassi","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2025090312263340000_9.1.e002859.10","doi-asserted-by":"crossref","first-page":"102452","DOI":"10.1016\/j.autrev.2019.102452","article-title":"Outcomes of limited cutaneous systemic sclerosis patients: results on more than 12,000 patients from the EUSTAR database","volume":"19","author":"Frantz","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2025090312263340000_9.1.e002859.11","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/S2665-9913(19)30144-4","article-title":"The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements","volume":"2","author":"Hoffmann-Vold","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2025090312263340000_9.1.e002859.12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025090312263340000_9.1.e002859.13","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025090312263340000_9.1.e002859.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.1795"},{"key":"2025090312263340000_9.1.e002859.15","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00161-2019","article-title":"Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases","volume":"54","author":"Wollin","year":"2019","journal-title":"Eur Respir J"},{"key":"2025090312263340000_9.1.e002859.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076"},{"key":"2025090312263340000_9.1.e002859.17","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/art.41668","article-title":"Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease","volume":"73","author":"Roofeh","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025090312263340000_9.1.e002859.18","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/art.41965","article-title":"Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: subgroup analyses by autoantibody status and modified rodnan skin thickness score","volume":"74","author":"Kuwana","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025090312263340000_9.1.e002859.19","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1093\/rheumatology\/keac091","article-title":"Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial","volume":"61","author":"Volkmann","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312263340000_9.1.e002859.20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir Med"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002859","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:26:41Z","timestamp":1756927601000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,2,16]]},"published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1136\/rmdopen-2022-002859"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002859","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}